/NRIX
NRIX Stock - Nurix Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$18.52+2.83%
+$0.51 (+2.83%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.99
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.45
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+54.8%upside
Target: $28.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for NRIX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$18.33 – $18.71
TARGET (TP)$28.67
STOP LOSS$17.04
RISK/REWARD1:6.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.88
52W High$22.50
52W Low$8.18
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $54.55M | $76.99M | $38.63M | $29.75M | $17.82M |
| Gross Profit | $-167,083,000 | $-112,161,000 | $-145,870,000 | $-86,684,000 | $-48,674,000 |
| Gross Margin | -306.3% | -145.7% | -377.6% | -291.4% | -273.1% |
| Operating Income | $-213,027,000 | $-155,063,000 | $-183,867,000 | $-117,886,000 | $-64,983,000 |
| Net Income | $-193,569,000 | $-143,948,000 | $-180,360,000 | $-117,194,000 | $-43,242,000 |
| Net Margin | -354.9% | -187.0% | -466.9% | -393.9% | -242.7% |
| EPS | $-2.88 | $-2.65 | $-3.71 | $-2.73 | $-2.76 |
Company Overview
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
91%
Hold / Neutral
1
9%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish1 Neutral/Bearish
Price Targets
$27
Average Target
↑ 48.1% Upside
Now
$11
Low
$27
Average
$41
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 24th 2025 | Truist | Resumed | Buy | $30 |
| October 21st 2025 | Mizuho | Initiation | Outperform | $24 |
| March 17th 2025 | Leerink Partners | Initiation | Market Perform | $16 |
| December 10th 2024 | BTIG Research | Initiation | Buy | $35 |
| December 6th 2024 | BMO Capital Markets | Initiation | Outperform | $35 |
| October 24th 2024 | UBS | Initiation | Buy | $35 |
| October 11th 2024 | Jefferies | Initiation | Buy | $41 |
| September 6th 2024 | Robert W. Baird | Resumed | Outperform | $26 |
| July 31st 2024 | Truist | Initiation | Buy | $36 |
| June 26th 2023 | Oppenheimer | Resumed | Outperform | $25 |
| March 9th 2023 | Barclays | Initiation | Overweight | $20 |
| February 28th 2023 | Oppenheimer | Initiation | Outperform | $25 |
| October 11th 2022 | Morgan Stanley | Initiation | Equal Weight | $11 |
| May 31st 2022 | Wells Fargo | Upgrade | Overweight | $25 |
Earnings History & Surprises
NRIXBeat Rate
39%
Last 18 quarters
Avg Surprise
-4.2%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$-1.03
Q4 2025
EPS Surprise History
Q1 24
-51.0%
$-0.77vs$-0.51
Q2 24
+5.0%
$-0.76vs$-0.80
Q3 24
-7.6%
$-0.71vs$-0.66
Q4 24
0.0%
$-0.67vs$-0.67
Q1 25
-11.9%
$-0.75vs$-0.67
Q2 25
+6.9%
$-0.67vs$-0.72
Q3 25
+26.8%
$-0.52vs$-0.71
Q4 25
-22.6%
$-1.03vs$-0.84
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 6, 2026 | — | — | — | — |
Q1 2026 | Jan 27, 2026 | $-0.86 | — | — | — |
Q4 2025 | Oct 9, 2025 | $-0.84 | $-1.03 | -22.6% | ✗ MISS |
Q3 2025 | Jul 9, 2025 | $-0.71 | $-0.52 | +26.8% | ✓ BEAT |
Q2 2025 | Apr 8, 2025 | $-0.72 | $-0.67 | +6.9% | ✓ BEAT |
Q1 2025 | Jan 28, 2025 | $-0.67 | $-0.75 | -11.9% | ✗ MISS |
Q4 2024 | Oct 11, 2024 | $-0.67 | $-0.67 | 0.0% | = MET |
Q3 2024 | Jul 11, 2024 | $-0.66 | $-0.71 | -7.6% | ✗ MISS |
Q2 2024 | Apr 10, 2024 | $-0.80 | $-0.76 | +5.0% | ✓ BEAT |
Q1 2024 | Feb 15, 2024 | $-0.51 | $-0.77 | -51.0% | ✗ MISS |
Q4 2023 | Oct 12, 2023 | $-0.69 | $-0.68 | +1.4% | ✓ BEAT |
Q3 2023 | Jul 13, 2023 | $-0.63 | $-0.45 | +28.6% | ✓ BEAT |
Q2 2023 | Apr 13, 2023 | $-0.90 | $-0.75 | +16.7% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $-0.68 | $-0.87 | -27.9% | ✗ MISS |
Q4 2022 | Oct 6, 2022 | $-0.99 | $-0.90 | +9.1% | ✓ BEAT |
Q3 2022 | Jul 7, 2022 | $-1.00 | $-1.01 | -1.0% | ✗ MISS |
Q2 2022 | Apr 7, 2022 | $-0.89 | $-0.95 | -6.7% | ✗ MISS |
Q1 2022 | Jan 27, 2022 | $-0.67 | $-0.85 | -26.9% | ✗ MISS |
Q4 2021 | Oct 14, 2021 | $-0.63 | $-0.65 | -3.2% | ✗ MISS |
Q3 2021 | Jul 13, 2021 | $-0.54 | $-0.60 | -11.1% | ✗ MISS |
Latest News
Wells Fargo Maintains Overweight on Nurix Therapeutics, Raises Price Target to $30
📈 PositiveBenzinga•Dec 16, 2025, 02:59 PM
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $30
📈 PositiveBenzinga•Dec 10, 2025, 02:39 PM
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $31
📈 PositiveBenzinga•Dec 10, 2025, 12:42 PM
BTIG Maintains Buy on Nurix Therapeutics, Raises Price Target to $30
📈 PositiveBenzinga•Dec 9, 2025, 06:52 PM
Nurix Therapeutics shares are trading higher after the company announced new clinical data from the Company's ongoing Phase 1a/1b NX-5948-301 study of bexobrutideg in patients with relapsed or refractory B-cell malignancies.
📈 PositiveBenzinga•Dec 8, 2025, 02:13 PM
Nurix Therapeutics To Present Phase 1 Bexobrutideg Data At ASH Annual Meeting Showing 75% Objective Response Rate
📈 PositiveBenzinga•Dec 8, 2025, 01:13 PM
Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target
📈 PositiveBenzinga•Dec 8, 2025, 12:15 PM
Reported Saturday, Nurix Advances Bexobrutideg NX-5948 Into Global DAYBreak-CLL-201 Phase 2 Enrollment Following Phase 1 Durability And Tolerability Data
📈 PositiveBenzinga•Dec 8, 2025, 09:13 AM
Nurix To Review Updated Phase 1 Clinical Data For Bexobrutideg During Webcast At ASH Annual Meeting
➖ NeutralBenzinga•Dec 1, 2025, 12:24 PM
Truist Securities Assumes Nurix Therapeutics at Buy, Raises Price Target to $30
📈 PositiveBenzinga•Nov 24, 2025, 06:13 PM
Nurix Therapeutics Releases New Translational Data From Its Ongoing Phase 1 Study Of NX-1607 Showing Dose-Dependent Pharmacologic Activity, Increased Peripheral T-Cell Activation And Proliferation, And Evidence Of Immune Engagement, Particularly In Patients With Stable Disease
📈 PositiveBenzinga•Nov 7, 2025, 02:03 PM
Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 10:46 AM
BTIG Reiterates Buy on Nurix Therapeutics, Maintains $27 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 10:40 AM
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Lowers Price Target to $28
➖ NeutralBenzinga•Oct 28, 2025, 11:55 AM
Wells Fargo Maintains Overweight on Nurix Therapeutics, Lowers Price Target to $21
➖ NeutralBenzinga•Oct 23, 2025, 01:16 PM
BTIG Maintains Buy on Nurix Therapeutics, Lowers Price Target to $27
➖ NeutralBenzinga•Oct 23, 2025, 09:57 AM
Needham Maintains Buy on Nurix Therapeutics, Lowers Price Target to $26
➖ NeutralBenzinga•Oct 22, 2025, 05:45 PM
Nurix Therapeutics shares are trading higher after the company announced the initiation of the DAYBreak clinical trial. The company announced the pricing of its $250 million offering of 24.5 million shares at $10.21 each.
📈 PositiveBenzinga•Oct 22, 2025, 01:35 PM
Nurix Therapeutics jumps after pricing $250M stock offering
📈 PositiveSeeking Alpha•Oct 22, 2025, 11:38 AM
Nurix Therapeutics Prices $250M Offering Of 24.5M Shares At $10.21 Each
➖ NeutralBenzinga•Oct 22, 2025, 11:23 AM
Frequently Asked Questions about NRIX
What is NRIX's current stock price?
Nurix Therapeutics, Inc. (NRIX) is currently trading at $18.52 per share. The stock has moved +2.83% today.
What is the analyst price target for NRIX?
The average analyst price target for NRIX is $28.67, based on 1 analyst.
What sector is Nurix Therapeutics, Inc. in?
Nurix Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is NRIX's market cap?
Nurix Therapeutics, Inc. has a market capitalization of $1.42 billion, making it a small-cap company.
Does NRIX pay dividends?
No, Nurix Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
FTRE
Fortrea Holdings Inc.
$17.74
Mkt Cap: $1.6B
KOD
Kodiak Sciences Inc.
$26.00
Mkt Cap: $1.4B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
URGN
UroGen Pharma Ltd.
$22.80
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to NRIX for comparison